Printer Friendly

GLIATECH APPOINTS WALCER VICE PRESIDENT OF BUSINESS DEVELOPMENT AND MARKETING

 CLEVELAND, March 2 /PRNewswire/ -- Gliatech Inc. today announced it has appointed Louis Walcer as vice president, business development and marketing. In this position, Mr. Walcer will be responsible for technology licensing, the development of corporate alliances and building a team to commercialize Gliatech's ADCON family of surgical adhesion prevention products currently under development. The lead product, ADCON-L, is currently in pivotal clinical trials in Europe and clinical trials are pending in the United States.
 "Lou is a tremendous addition to our management team," said Thomas O. Oesterling, Ph.D., president and chief executive officer of Gliatech. "His international experience in all aspects of business planning is a tremendous asset as we move ADCON-L toward commercialization."
 Previously, Mr. Walcer, age 40, spent nine years at Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP), in a variety of marketing and business development positions, most recently as director, business development and commercial analysis. At Wyeth- Ayerst Laboratories he was responsible for global acquisition, merger, joint venture, licensing, and copromotion activities.
 Prior to joining Wyeth-Ayerst in 1984, he was a product manager at Schering Corporation, working with central nervous system, anticancer and antiviral products.
 Mr. Walcer received a MBA from New York University Graduate School of Business Administration and a BA from Cornell University.
 Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on an understanding of properties of glial cells, a major component of the nervous system.
 -0- 3/2/93
 /CONTACT: Thomas O. Oesterling, Ph.D., president of Gliatech Inc., 216-831-3200, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-979-9180, for Gliatech Inc./


CO: Gliatech Inc. ST: Ohio IN: MTC SU: PER

SM-OS -- NY021 -- 7988 03/02/93 09:24 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 2, 1993
Words:288
Previous Article:ALLEN J. KROWE ELECTED VICE CHAIRMAN OF TEXACO INC.; SENIOR OFFICIAL ALSO ADDED TO TEXACO BOARD OF DIRECTORS: APPOINTMENT EFFECTIVE APRIL 1
Next Article:COREL AND NCR FORGE STRATEGIC SCSI ALLIANCE
Topics:


Related Articles
GLIATECH APPOINTS SCHERING-PLOUGH EXECUTIVE VICE PRESIDENT OF PRODUCT DEVELOPMENT
GLIATECH BEGINS U.S. CLINICAL TRIAL FOR ADCON-L -- PRODUCT TO INHIBIT SURGICAL ADHESIONS AFTER BACK SURGERY --
GLIATECH RECEIVES ISO 9001 CERTIFICATION
GLIATECH RECEIVES EUROPEAN REGULATORY APPROVAL FOR ADCON-L ADHESION CONTROL PRODUCT
Gliatech and Chugai Sign Exclusive License Agreement
Gliatech Receives FDA Approval to Initiate Clinical Trials of ADCON(R)-P
Gliatech Reports 1997 Fourth Quarter and Year End Results
Gliatech Announces Stock Offering of Newly Issued Shares
Gliatech Appoints John A. Redmond Vice President, General Manager Medical Devices.
Gliatech Announces New Management Positions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters